Product Description
Roxithromycin EP/BP /CPsupplier Pharmaceutical API Antibiotic 80214-83-1
AI Product Description
*The following content is generated by AI and is for reference only.
Roxithromycin is a semi-synthetic macrolide antibiotic derived from erythromycin, specifically engineered to overcome the limitations of its predecessor regarding acid stability and bioavailability. Recognized under major pharmacopoeial standards including the European Pharmacopoeia (EP), British Pharmacopoeia (BP), and Chinese Pharmacopoeia (CP), this pharmaceutical API serves as a critical agent in treating various bacterial infections. Its molecular formula is C31H47NO13, and it is identified by the CAS Registry Number 80214-83-1. Structurally, Roxithromycin features an oxime ether group at the C9 position, which significantly enhances its resistance to gastric acid degradation compared to erythromycin.
This antibiotic functions primarily by inhibiting bacterial protein synthesis. It binds reversibly to the 50S subunit of the bacterial ribosome, thereby blocking the translocation step during peptide chain elongation. This mechanism effectively halts the growth of susceptible organisms without necessarily killing them immediately, classifying it as bacteriostatic, though it can be bactericidal at high concentrations or against highly sensitive strains. Roxithromycin demonstrates broad-spectrum activity against Gram-positive bacteria, such as Streptococcus pneumoniae and Staphylococcus aureus, as well as certain Gram-negative pathogens like Haemophilus influenzae and Moraxella catarrhalis. Additionally, it exhibits efficacy against atypical pathogens including Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila.
Clinically, Roxithromycin is widely prescribed for respiratory tract infections, including acute bronchitis, pneumonia, pharyngitis, and tonsillitis. It is also utilized in the management of skin and soft tissue infections, as well as otitis media. Due to its favorable pharmacokinetic profile, characterized by rapid absorption and a long half-life, it allows for convenient once-daily dosing regimens. The drug is generally well-tolerated, with gastrointestinal disturbances being the most common adverse effects. As a high-quality API supplied by leading global manufacturers, Roxithromycin remains a cornerstone therapy in antimicrobial stewardship programs worldwide, offering a reliable alternative for patients who cannot tolerate beta-lactams or require extended coverage for respiratory pathogens.